Regeneron’s cocktail antibody, REGN-COV2; J&J’s manufacturing-spree; ObsEva’s Yselty top-line studies
Jul 7, 2020
Regeneron Pharmaceuticals launches the Phase III trials of REGN-COV2 for treatment and prevention of COVID-19. Regeneron is running two trials simultaneously, one for pr...
Read More
Regeneron’s I-O Drug; Gene Therapy for Parkinson’s Disease; Yumanity and Merck Inks $500M Deal; Simcha Raises $25M
Jul 6, 2020
Regeneron recognizes new combos to boost I-O drug Libtayo’s cancer response PD-1/L1 inhibitors work by enhancing the immune response to cancer, have benefitted patien...
Read More
Sarepta & Codiak Inks $72.5M Deal; Invitae to Acquires ArcherDX; Merck announces V114’s Phase III result
Jul 6, 2020
Sarepta Therapeutics has announced a research and option alliance with Codiak BioSciences to design and develop engineered exosome therapeutics for neuromuscular diseases T...
Read More
Lassen’s anti-IL-11 antibody; PTC’s COVID-19 trial; Lenzilumab’s result; Orca raises $192M
Jul 6, 2020
Lassen Therapeutics to create anti-IL-11 antibody for cancer and fibrosis Lassen Therapeutics is revealing USD 31 million from Frazier Healthcare Partners, Alta Venture and...
Read More
HCQ/ CQ failure; AZ/ Catalent’s deal; Sinovac’s CoronaVac and Lilly’s Olumiant trial results
Jun 16, 2020
The US FDA nullified the Emergency Use Authorization (EUA) granted to chloroquine phosphate and hydroxychloroquine sulfate to treat COVID-19. The regulatory authority had g...
Read More
Alnylam’s lumasiran results; AZ’s oncology drug; Astellas Roxadustat; Evotec’s partnership with ABL
Jun 29, 2020
Alnylam Pharmaceuticals has released the Phase III results of the clinical trial ILLUMINATE-A evaluating lumasiran for Primary Hyperoxaluria Type 1 Primary Hyperoxaluria Ty...
Read More
Gene-edited T cells for diabetes treatment; Pliant raised $144 million; Accent, AstraZeneca aim RNA modifiers in cancer deal; NodThera Raises $55M;
Jun 4, 2020
Gene-edited T cells for diabetes treatment The Scientists at the Seattle Children’s Research Institute and the Benaroya Research Institute have got a promising findin...
Read More
Startup focuses tumors with CAR-T; AbCellera grabs USD 105M; Gilead inks USD 2B deal; GSK’s anti-BCMA antibody receives a boost
Jun 29, 2020
The startup focuses on glioblastoma tumors with CAR-T therapy. CAR-T technology that involves genetically modifying a patient’s immune cells to recognize and attack cance...
Read More
CanSino deals with Precision; Atea raises USD 215 M; Applied Molecular Transport targets for USD 100 M IPO; Cell therapy repairs multiple sclerosis in mice
Jun 29, 2020
CanSino adds mRNA with Precision NanoSystems CanSino Biologics is already evaluating a recombinant coronavirus vaccine in China. However, it is adding the mRNA to COV...
Read More
Mavacamten Phase III clinical trial, FDA nod for Ovarian cancer therapy, Dyno Therapeutics & Novartis Collaboration, Abbott’s COVID-19 diagnostic kit
May 12, 2020
MyoKardia has announced the promising results of Phase III clinical trials of its lead drug mavacamten for symptomatic, obstructive hypertrophic cardiomyopathy (HCM). Follo...
Read More
Avrobio taps Magenta’s ADC; Eli Lilly ramps up; FDA postpones decision; CSL gears up to fight pandemic,
May 7, 2020
Avrobio taps ADC of Magenta for enhancing gene therapy conditioning Avrobio is working to make conditioning safer. The company is collaborating with Magenta Therapeutics to...
Read More
Acquisition of Stemline; Roche’s Elecsys Anti-SARS-CoV-2 antibody test; Newron’s abandonment of STARS trial
May 5, 2020
Florence-based Menarini Group has announced a USD667 million acquisition of the Stemline Therapeutics, an oncology-focused company. As per the agreement, Menarini plans to ...
Read More
Remdesivir accelerates for COVID-19 recovery; Merck pact with Almac; Pfizer, BioNTech finish dosing in; Taysha Gene Therapies for trials
Jun 25, 2020
Remdesivir of Gilead accelerates COVID-19 recovery Gilead Sciences’ Remdesivir shows the first data from a placebo-controlled study. Remdesivir decreases recovery tim...
Read More
In the race to fight SARS-CoV-2: Merck, ISB; ViiV; Genalyte gears up
Jul 2, 2020
Merck has collaborated with the Seattle-based Institute for Systems Biology (ISB) to further study novel coronavirus SARS-CoV-2. The primary goal of the collaboration will ...
Read More
AbbVie, Sofinnova back; Gilead, Kite ink; Biogen aims filing; Reversing diabetes
Jun 29, 2020
AbbVie, Sofinnova back USD 38 Million for Nitrome Biosciences Nitrome Biosciences contemplates treating Parkinson’s disease and diabetes by targeting a new class of e...
Read More
